ÂÜÀòÂÒÂ×

Rachel Legmann is an accomplished professional in the field of gene therapy and biotechnology, currently serving as the Senior Director of Technology for Gene Therapy at Repligen Corporation since February 2021. With over two decades of experience, Rachel has held various leadership roles including Director of Technical Consultancy at Pall Corporation and Manager of Cell Culture Development at Goodwin Biotechnology, Inc. Rachel's expertise encompasses vector-based therapeutics, process development, and the scale-up of mammalian cell culture processes for therapeutic applications. Educational credentials include a Ph.D. in Food Engineering and Biotechnology from the Technion - Israel Institute of Technology, complemented by postdoctoral training in biotechnology at Tel Aviv University and a Bachelor's degree in Biology from The Hebrew University of Jerusalem.